Inspection·February 5, 2026

F 0755 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Few Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a licensed pharmacist. **NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** THE FOLLOWING DEFICIENCY REPRESENTS AN INCIDENT OF PAST NON-COMPLIANCE THAT WAS SUBSEQUENTLY CORRECTED PRIOR TO THIS SURVEY. Based on record review, staff interview, resident interview, observation of the 100-hall medication cart, and policy review, the facility failed to administer an as needed seizure medication for a resident having a seizure. This affected one (#17) of three residents reviewed for as needed seizure medications. The facility census was 64. Findings include:Review of Resident #17's medical record revealed an admission date of 08/06/25. Diagnoses included epilepsy, intractable without status epilepticus, type two diabetes mellitus, moderate persistent asthma, anxiety, orthostatic hypotension and peripheral vascular disease.Review of Resident #17's quarterly Minimum Data Set (MDS) dated [DATE] revealed Resident #17 had intact cognition with a Brief Interview for Mental Status (BIMS) score of 14. Furthermore, Resident #17 was noted to take anticonvulsant medication.Review of Resident #17's current physician orders revealed an order for Divalproex Sodium oral tablet delayed release 500 milligrams (mg) with instructions to give three tablets by mouth every morning and at bedtime for seizures. An order for Levetiracetam oral tablet 1000 mg with instructions to give one and a half tablets by mouth two times a day for seizures. An order for Levetiracetam oral tablet 750 mg with instructions to give one tablet by mouth every morning and at bedtime for seizures. An order for Primidone oral tablet 50 mg with instructions to give one tablet by mouth three times a day for anticonvulsant. An order for Topiramate oral tablet 200 mg with instructions to give one tablet by mouth every morning and at bedtime for seizures. An order for Midazolam nasal solution 5 mg/0.1 milliliter (ml) with instructions to give one spray in the left nostril as needed for a seizure lasting greater than two minutes, may repeat dose in alternate nostril if seizure continues. Do not repeat dose if the resident is having trouble breathing or sedation.Review of Resident #17's care plan dated 01/28/26 revealed Resident #17 received anticonvulsant medication and was at risk for adverse side effects with interventions that included to administer medications as ordered by the physician and to observe Resident #17 closely for significant side effects of anticonvulsant medication use that included but is not limited to dizziness, nausea, jaundice, and blurred vision.Review of Resident #17's Medication Administration Record (MAR) for the month of January 2026 revealed prior to Resident #17's seizure on 01/29/26, Resident #17 received all her scheduled seizure medications as ordered. On 01/29/26 when Resident #17 had her seizure, the as needed seizure medication was not documented as administered.Interview and concurrent observation on 02/05/26 at 2:40 P.M. of the 100-hall medication cart with Registered Nurse (RN) #112 revealed Resident #17 had four doses of the as needed Midazolam in the medication cart in the event of a seizure. RN #112 stated she had been educated about leaving the keys to the medication cart with another nurse when going on break.Interview on 02/05/26 at 3:03 P.M. with Certified Nursing Assistant (CNA) #163 revealed he had just started his shift and noticed Resident #17's call light was on. CNA #163 stated he answered the call light and (continued on next page) Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation. LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE (X6) DATE FORM CMS-2567 (02/99) Previous Versions Obsolete Facility ID: If continuation sheet Page 1 of 2 Event ID: 366039 Printed: 05/15/2026 Form Approved OMB No. 0938-0391 Department of Health & Human Services Centers for Medicare & Medicaid Services STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: (X2) MULTIPLE CONSTRUCTION 366039 B. Wing A. Building (X3) DATE SURVEY COMPLETED 02/05/2026 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE Majestic Care of Point Place 6101 N Summit St Toledo, OH 43611 For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency. (X4) ID PREFIX TAG SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)